Core Viewpoint - Watson Bio's stock has experienced fluctuations, with a recent decline of 2.07% and a total market capitalization of 19.72 billion yuan, reflecting ongoing challenges in revenue and profit margins [1][2]. Financial Performance - For the period from January to September 2025, Watson Bio reported a revenue of 1.719 billion yuan, a year-on-year decrease of 19.73%, and a net profit attributable to shareholders of 163 million yuan, down 36.24% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 403 million yuan, with 47.98 million yuan distributed over the past three years [2]. Stock Market Activity - As of November 18, Watson Bio's stock price was 12.33 yuan per share, with a trading volume of 385 million yuan and a turnover rate of 1.99% [1]. - The stock has seen a year-to-date increase of 2.15%, but a decline of 3.82% over the last five trading days [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 2.75% to 114,000, while the average number of circulating shares per person increased by 2.83% to 13,643 shares [2]. - The largest circulating shareholder is E Fund's ChiNext ETF, holding 34.47 million shares, a decrease of 5.80 million shares from the previous period [2].

Core Viewpoint - Watson Bio's stock has experienced a decline in price and significant net outflow of funds, indicating potential challenges in its market performance and investor sentiment [1][2]. Financial Performance - As of June 30, Watson Bio reported a revenue of 1.154 billion yuan, a year-on-year decrease of 19.47% [2]. - The net profit attributable to shareholders was 43.16 million yuan, reflecting a substantial year-on-year decline of 74.69% [2]. - Cumulative cash dividends since the company's A-share listing amount to 403 million yuan, with 47.98 million yuan distributed over the past three years [3]. Stock Market Activity - On October 23, Watson Bio's stock price fell by 2.07%, trading at 11.35 yuan per share, with a total market capitalization of 18.153 billion yuan [1]. - The stock has decreased by 5.97% year-to-date, with a 1.56% drop over the last five trading days and an 8.25% decline over the past 20 days [1]. - The company experienced a net outflow of 13.09 million yuan in principal funds, with significant selling pressure observed [1]. Shareholder Structure - As of June 30, the number of shareholders increased to 117,300, while the average number of circulating shares per person decreased by 3.88% to 13,268 shares [2]. - The largest circulating shareholder is E Fund's ChiNext ETF, holding 40.2718 million shares, a decrease of 1.0618 million shares from the previous period [3]. - Other notable shareholders include the China National Securities Bio-Medical Index A and Southern CSI 500 ETF, with varying changes in their holdings [3]. Company Overview - Watson Bio, established on January 16, 2001, and listed on November 12, 2010, specializes in the research, production, and sales of vaccine products [1]. - The company's revenue composition includes 94.82% from self-developed vaccines, 4.67% from intermediate products, and minor contributions from other services [1].

Core Viewpoint - Watson Bio's stock has shown fluctuations with a recent increase of 2.02%, but the year-to-date performance indicates a decline of 3.73% [1] Financial Performance - For the first half of 2025, Watson Bio reported revenue of 1.154 billion yuan, a year-on-year decrease of 19.47% [2] - The net profit attributable to shareholders for the same period was 43.16 million yuan, down 74.69% year-on-year [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 117,300, a rise of 3.73% from the previous period [2] - The average number of circulating shares per shareholder decreased by 3.88% to 13,268 shares [2] Dividend Distribution - Since its A-share listing, Watson Bio has distributed a total of 403 million yuan in dividends, with 47.98 million yuan distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, the largest circulating shareholder is E Fund's ChiNext ETF, holding 40.27 million shares, a decrease of 1.0618 million shares from the previous period [3] - The third-largest shareholder is the China National Bio-Medical Index A, holding 26.98 million shares, down by 2.1952 million shares [3] - The fifth-largest shareholder is the Southern CSI 500 ETF, which increased its holdings by 3.1893 million shares to 23.81 million shares [3]

Company Overview - Watson Bio, established on January 16, 2001, and listed on November 12, 2010, is located in Kunming, Yunnan Province. The company specializes in the research, production, and sales of vaccine products [1] - The main revenue composition includes self-developed vaccine products (94.82%), intermediate products (4.67%), other (supplement) (0.26%), and technical services (0.24%) [1] Financial Performance - For the first half of 2025, Watson Bio reported a revenue of 1.154 billion yuan, a year-on-year decrease of 19.47%. The net profit attributable to shareholders was 43.16 million yuan, down 74.69% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 403 million yuan, with 47.98 million yuan distributed over the past three years [3] Stock Performance - As of September 19, Watson Bio's stock price was 11.95 yuan per share, with a market capitalization of 19.112 billion yuan. The stock has decreased by 0.99% year-to-date and by 3.94% over the last five trading days [1] - The stock experienced a net outflow of 37.44 million yuan in principal funds, with significant selling pressure observed [1] Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 117,300, while the average circulating shares per person decreased by 3.88% to 13,268 shares [2] - The largest circulating shareholder is E Fund's ChiNext ETF, holding 40.27 million shares, a decrease of 1.0618 million shares from the previous period [3]